Readnour Robin Shane's Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Jan 12, 2024
- Accession no.
- 0001209191-24-001537
- Filed
- Jan 12, 2024
- Trade date
- Jan 10, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $80.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Readnour Robin ShaneCIK 0001914883 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 10, 2024 | Common Stock | SSaleDisposed | −1,869 | $21.93 | −$40,987.17 | 415,494 | Indirect | |
| Jan 10, 2024 | Common Stock | SSaleDisposed | −1,800 | $21.92 | −$39,456 | 485,792 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.